Cantargia announces the publication of two scientific articles on nadunolimab

Cantargia AB today announced the publication of two articles in peer-reviewed scientific journals. The first, published in the British Journal of Cancer, presents the results of the phase 1 part of the CANFOUR clinical trial where the safety of nadunolimab was evaluated. The second, published in Frontiers in Immunology, presents results related to functional, biophysical and structural analyzes of interactions between nadunolimab and its IL1RAP target.

STOCKHOLM, December 28, 2021 / PRNewswire / – Cantargia today announced the publication of two articles in peer-reviewed scientific journals.

The first article, published in the British Journal of Cancer and written by Robbrecht et al, is titled “First dose escalation phase 1 human study of CAN04, a first-class antibody to the accessory interleukin-1 receptor protein (IL1RAP) in patients with solid tumors” . This publication focuses on the results obtained for Cantargia’s most advanced program, nadunolimab, in the phase 1 portion of the ongoing CANFOUR Phase 1 / 2a clinical trial. Part of this data was presented at the ASCO 2019 conference. The article is available through the following link:

The second article, published in Frontiers in Immunology and written by Fields et al, is entitled “Molecular basis of the selective inhibition of cytokine signaling by antibodies targeting a shared receptor”. This publication details the functional, biophysical and structural analyzes of the interaction between nadunolimab, or other antibodies, against the IL1RAP target. The data show that targeting of distinct binding sites on IL1RAP by anti-IL1RAP antibodies results in differential blockade of signaling by IL-1, IL-33 and IL-36. This study was carried out in collaboration with Prof. Eric J Sundberg at University of Maryland. The article is available via the following link:

For more information, please contact
Göran Forsberg, CEO
Telephone: +46 (0) 46-275 62 60
Email: [email protected]

This information was submitted for publication at 2:30 p.m. CET on December 28, 2021.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the IL1RAP protein, implicated in a number of forms of cancer and inflammatory diseases. The main project, the nadunolimab antibody (CAN04), is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Intermediate positive data from the combination with chemotherapy indicate greater efficacy than expected from chemotherapy alone. Cantargia’s second project, the CAN10 antibody, focuses on the treatment of severe autoimmune / inflammatory diseases, initially focusing on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (Stockholm: CANTA). More information about Cantargia is available at

About nadunolimab (CAN04)
The CAN04 antibody binds tightly to its IL1RAP target and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Thus, CAN04 may counteract the contribution of the IL-1 system to the immunosuppressive tumor microenvironment and the development of resistance to chemotherapy. CAN04 is being studied in several ongoing clinical trials. In the CANFOUR phase I / IIa study, first-line combination therapy is being studied with standard chemotherapies in patients with PDAC (gemcitabine / nab-paclitaxel) and patients with NSCLC (cisplatin / gemcitabine) (NCT03267316). Intermediate positive data for combination therapies show durable responses or pseudo-progression in patients with PDAC, resulting in a median iPFS of 7.8 months and a median survival of 12.6 months. Higher efficacy was also observed in patients with NSCLC with a median PFS of 7.2 months. A response rate of 53% was observed in patients with non-squamous NSCLC, with even higher responses in patients previously treated with pembrolizumab. These results show greater efficacy than that expected from chemotherapy alone. CAN04 is also being studied with chemotherapy in the phase I CAPAFOUR study, with the FOLFIRINOX regimen for the first-line treatment of metastatic PDAC (NCT04990037), and in two other clinical studies, CESTAFOUR (NCT05116891) and TRIFOUR, in other forms of cancer, including cancer of the biliary tract, colorectal cancer and triple negative breast cancer. CAN04 is also being evaluated with the immune checkpoint inhibitor pembrolizumab, with or without chemotherapy, in the phase I study CIRIFOUR (NCT04452214).

This information was brought to you by Cision,c3479217

The following files are available for download:

Jacob L. Thornton